Efficacy of 7-day and 14-day bismuth-containing quadruple therapy and 7-day and 14-day moxifloxacin-based triple therapy as second-line eradication for Helicobacter pylori infection

Gut and Liver

Volumn 9, Issue 4, 2015, Pages 478-485

  Lee, Seong Tae ^a   Lee, Dong Ho ^a   Lim, Ji Hyun ^a   Kim, Nayoung ^a   Park, Young Soo ^a   Shin, Cheol Min ^a   Jo, Hyun Jin ^a   Song, In Sung ^a  

^a Seoul National University Bundang Hospital   (South Korea)

Author keywords

Bismuth containing quadruple regimen; Helicobacter pylori; Moxifloxacin based triple regimen; Second line therapy

Indexed keywords

AMOXICILLIN; BISMUTH CITRATE; CARBON 13; CLARITHROMYCIN; ESOMEPRAZOLE; LANSOPRAZOLE; METRONIDAZOLE; MOXIFLOXACIN; OMEPRAZOLE; PANTOPRAZOLE; PROTON PUMP INHIBITOR; RABEPRAZOLE; TETRACYCLINE; ANTACID AGENT; ANTIINFECTIVE AGENT; BISMUTH; QUINOLONE DERIVATIVE;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; BLOATING; DIARRHEA; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG EFFICACY; DRUG TREATMENT FAILURE; ERADICATION THERAPY; FEMALE; HEADACHE; HELICOBACTER INFECTION; HELICOBACTER PYLORI; HISTOLOGY; HUMAN; INTENTION TO TREAT ANALYSIS; KOREA; MAJOR CLINICAL STUDY; MALE; MEDICATION COMPLIANCE; NAUSEA; NONHUMAN; PATIENT COMPLIANCE; RAPID UREASE TEST; TASTE DISORDER; TREATMENT DURATION; UREA BREATH TEST; URTICARIA; VOMITING; WEAKNESS; AGED; COMBINATION DRUG THERAPY; COMPARATIVE STUDY; DRUG ADMINISTRATION; HELICOBACTER INFECTIONS; MIDDLE AGED; PROCEDURES; RETROSPECTIVE STUDY; TREATMENT OUTCOME;

ADULT; AGED; AMOXICILLIN; ANTACIDS; ANTI-INFECTIVE AGENTS; BISMUTH; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; FEMALE; FLUOROQUINOLONES; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INTENTION TO TREAT ANALYSIS; MALE; METRONIDAZOLE; MIDDLE AGED; PROTON PUMP INHIBITORS; RETROSPECTIVE STUDIES; TETRACYCLINE; TREATMENT OUTCOME;

EID: 84936990950     PISSN: 19762283     EISSN: 20051212     Source Type: Journal    
DOI: 10.5009/gnl14020     Document Type: Article

References (46)

1. McColl KE. Clinical practice: Helicobacter pylori infection. N Engl J Med 2010;362:1597-1604.
2. Malfertheiner P, Megraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht III Consensus Report. Gut 2007;56:772-781.
3. Chey WD, Wong BC; Practice Parameters Committee of the American College of Gastroenterology. American College of Gastroenterology guideline on the management of Helicobacter pylori infection. Am J Gastroenterol 2007;102:1808-1825.
4. Fischbach W, Malfertheiner P, Hoffmann JC, et al. S3-guideline "Helicobacter pylori and gastroduodenal ulcer disease" of the German Society for Digestive and Metabolic Diseases (DGVS) in cooperation with the German Society for Hygiene and Microbiology, Society for Pediatric Gastroenterology and Nutrition e. V., German Society for Rheumatology, AWMF-registration-no. 021/001. Z Gastroenterol 2009;47:1230-1263.
5. Kim BG, Lee DH, Ye BD, et al. Comparison of 7-day and 14-day proton pump inhibitor-containing triple therapy for Helicobacter pylori eradication: neither treatment duration provides acceptable eradication rate in Korea. Helicobacter 2007;12:31-35.
6. Kim N, Kim JJ, Choe YH, et al. Diagnosis and treatment guidelines for Helicobacter pylori infection in Korea. Korean J Gastroenterol 2009;54:269-278.
7. Graham DY, Fischbach L. Helicobacter pylori treatment in the era of increasing antibiotic resistance. Gut 2010;59:1143-1153.
8. Gisbert JP, Pajares R, Pajares JM. Evolution of Helicobacter pylori therapy from a meta-analytical perspective. Helicobacter 2007;12 Suppl 2:50-58.
9. Della Monica P, Lavagna A, Masoero G, Lombardo L, Crocellá L, Pera A. Effectiveness of Helicobacter pylori eradication treatments in a primary care setting in Italy. Aliment Pharmacol Ther 2002;16:1269-1275.
10. O'Connor A, Gisbert JP, McNamara D, O'Morain C. Treatment of Helicobacter pylori infection 2010. Helicobacter 2010;15 Suppl 1:46-52.
11. O'Connor A, Gisbert JP, McNamara D, O'Morain C. Treatment of Helicobacter pylori infection 2011. Helicobacter 2011;16 Suppl 1:53-58.
12. Gisbert JP, Calvet X. Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough. Aliment Pharmacol Ther 2011;34:1255-1268.
13. Malfertheiner P, Mégraud F, O'Morain C, et al. Current concepts in the management of Helicobacter pylori infection: the Maastricht 2-2000 Consensus Report. Aliment Pharmacol Ther 2002;16:167-180.
14. Hojo M, Miwa H, Nagahara A, Sato N. Pooled analysis on the efficacy of the second-line treatment regimens for Helicobacter pylori infection. Scand J Gastroenterol 2001;36:690-700.
15. Gisbert JP, Pajares JM. Review article: Helicobacter pylori "rescue" regimen when proton pump inhibitor-based triple therapies fail. Aliment Pharmacol Ther 2002;16:1047-1057.
16. Keating GM, Scott LJ. Moxifloxacin: a review of its use in the management of bacterial infections. Drugs 2004;64:2347-2377.
17. Krasemann C, Meyer J, Tillotson G. Evaluation of the clinical microbiology profile of moxifloxacin. Clin Infect Dis 2001;32 Suppl 1:S51-S63.
18. Di Caro S, Ojetti V, Zocco MA, et al. Mono, dual and triple moxifloxacin-based therapies for Helicobacter pylori eradication. Aliment Pharmacol Ther 2002;16:527-532.
19. Nista EC, Candelli M, Zocco MA, et al. Moxifloxacin-based strategies for first-line treatment of Helicobacter pylori infection. Aliment Pharmacol Ther 2005;21:1241-1247.
20. Bago P, Vcev A, Tomic M, Rozankovic M, Marusić M, Bago J. High eradication rate of H. pylori with moxifloxacin-based treatment: a randomized controlled trial. Wien Klin Wochenschr 2007;119:372-378.
21. Cheon JH, Kim N, Lee DH, et al. Efficacy of moxifloxacin-based triple therapy as second-line treatment for Helicobacterpylori infection. Helicobacter 2006;11:46-51.
22. Bago J, Pevec B, Tomić M, Marusić M, Bakula V, Bago P. Secondline treatment for Helicobacter pylori infection based on moxifloxacin triple therapy: a randomized controlled trial. Wien Klin Wochenschr 2009;121:47-52.
23. Li Y, Huang X, Yao L, Shi R, Zhang G. Advantages of moxifloxacin and levofloxacin-based triple therapy for second-line treatments of persistent Helicobacter pylori infection: a meta analysis. Wien Klin Wochenschr 2010;122:413-422.
24. Kang JM, Kim N, Lee DH, et al. Second-line treatment for Helicobacter pylori infection: 10-day moxifloxacin-based triple therapy versus 2-week quadruple therapy. Helicobacter 2007;12:623-628.
25. Cellini L, Grande R, Di Campli E, Di Bartolomeo S, Capodicasa S, Marzio L. Analysis of genetic variability, antimicrobial susceptibility and virulence markers in Helicobacter pylori identified in Central Italy. Scand J Gastroenterol 2006;41:280-287.
26. Wang LH, Cheng H, Hu FL, Li J. Distribution of gyrA mutations in fluoroquinolone-resistant Helicobacter pylori strains. World J Gastroenterol 2010;16:2272-2277.
27. Chung KH, Lee DH, Jin E, et al. The efficacy of moxifloxacincontaining triple therapy after standard triple, sequential, or concomitant therapy failure for Helicobacter pylori eradication in Korea. Gut Liver 2014;8:605-611.
28. Moon JY, Kim GH, You HS, et al. Levofloxacin, metronidazole, and lansoprazole triple therapy compared to quadruple therapy as a second-line treatment of Helicobacter pylori infection in Korea. Gut Liver 2013;7:406-410.
29. Lee JH, Shin JH, Roe IH, et al. Impact of clarithromycin resistance on eradication of Helicobacter pylori in infected adults. Antimicrob Agents Chemother 2005;49:1600-1603.
30. Kim JY, Kim N, Park HK, et al. Primary antibiotic resistance of Helicobacter pylori strains and eradication rate according to gastroduodenal disease in Korea. Korean J Gastroenterol 2011;58:74-81.
31. Mock T, Yatscoff R, Foster R, et al. Clinical validation of the Helikit: a 13C urea breath test used for the diagnosis of Helicobacter pylori infection. Clin Biochem 1999;32:59-63.
32. Megraud F. Helicobacter pylori and antibiotic resistance. Gut 2007;56:1502.
33. Parente F, Cucino C, Bianchi Porro G. Treatment options for patients with Helicobacter pylori infection resistant to one or more eradication attempts. Dig Liver Dis 2003;35:523-528.
34. Mégraud F. H pylori antibiotic resistance: prevalence, importance, and advances in testing. Gut 2004;53:1374-1384.
35. Lee JW, Kim N, Kim JM, et al. Prevalence of primary and secondary antimicrobial resistance of Helicobacter pylori in Korea from 2003 through 2012. Helicobacter 2013;18:206-214.
36. Mégraud F, Lamouliatte H. Review article: the treatment of refractory Helicobacter pylori infection. Aliment Pharmacol Ther 2003;17:1333-1343.
37. Mégraud F, Lehours P. Helicobacter pylori detection and antimicrobial susceptibility testing. Clin Microbiol Rev 2007;20:280-322.
38. Lee BH, Kim N, Hwang TJ, et al. Bismuth-containing quadruple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate in Korea. Helicobacter 2010;15:38-45.
39. Nishizawa T, Suzuki H, Hibi T. Quinolone-based third-line therapy for Helicobacter pylori eradication. J Clin Biochem Nutr 2009;44:119-124.
40. Yoon H, Kim N, Lee BH, et al. Moxifloxacin-containing triple therapy as second-line treatment for Helicobacter pylori infection: effect of treatment duration and antibiotic resistance on the eradication rate. Helicobacter 2009;14:77-85.
41. Miyachi H, Miki I, Aoyama N, et al. Primary levofloxacin resistance and gyrA/B mutations among Helicobacter pylori in Japan. Helicobacter 2006;11:243-249.
42. Kim JM, Kim JS, Kim N, Jung HC, Song IS. Distribution of fluoroquinolone MICs in Helicobacter pylori strains from Korean patients. J Antimicrob Chemother 2005;56:965-967.
43. Zou J, Yang ZX, Qin ZM. Laboratory and clinical study of levofloxacin against Helicobacter pylori. Zhonghua Yi Xue Za Zhi 2003;83:1778-1781.
44. Chung JW, Lee GH, Jeong JY, et al. Resistance of Helicobacter pylori strains to antibiotics in Korea with a focus on fluoroquinolone resistance. J Gastroenterol Hepatol 2012;27:493-497.
45. Qasim A, O'Morain CA. Review article: treatment of Helicobacter pylori infection and factors influencing eradication. Aliment Pharmacol Ther 2002;16 Suppl 1:24-30.
46. Graham DY, Lu H, Yamaoka Y. A report card to grade Helicobacter pylori therapy. Helicobacter 2007;12:275-278.